Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
regarding the safety or efficacy of any generic atorvastatin at this time, including the Mylan product which was cited in the recent press accounts.

We are aware that AE reports in FAERS often refer to the brand name product and manufacturer (rather than to the specific generic products and corresponding manufacturers) as the providing manufacturers, and those reports can far exceed the brand products percentage of prescriptions dispensed when compared with generic products.

But this is not s
16/35 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/19 21:08